​

Corresponding author * 

Prime assembly with linear DNA donors enables large genomic insertions.

Bin Liu*, Andrew Petti, Xuntao Zhou, Haoyang Cheng, Lin Zhou, Tingting Jiang, Erik J. Sontheimer*, Wen Xue*.

bioRxiv [Preprint]. 2025 Jun. https://www.biorxiv.org/content/10.1101/2025.06.16.659978v1

​

Targeted genome editing with a DNA-dependent DNA polymerase and exogenous DNA-containing templates.

Bin Liu, Xiaolong Dong, Chunwei Zheng, David Keener, Zexiang Chen, Haoyang Cheng, Jonathan K. Watts, Wen Xue*, and Erik J. Sontheimer*.  

Nature Biotechnology. 2024. Jul;42 (7): 1039-1045. https://www.nature.com/articles/s41587-023-01947-w

​

A modular prime editor with untethered reverse transcriptase and circular RNA template. 

Bin Liu, Xiaolong Dong, Haoyang Cheng, Chunwei Zheng, Zexiang Chen, Tomás C. Rodríguez, Shun-Qing Liang, Wen Xue*, Erik J. Sontheimer*.

Nature Biotechnology. 2022 Sep;40(9):1388-1393. https://www.nature.com/articles/s41587-022-01255-9

​

Inhibition of Histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR/Cas9-mediated gene editing.

Bin Liu*, Siwei Chen, Anouk La Rose, Deng Chen,  Fangyuan Cao, Martijn Zwinderman,Dominik Kiemel, Manon Aïssi, Dekker FJ, Haisma  HJ*.

Nucleic Acids Research. 2020 Jan 24;48(2):517-532. https://academic.oup.com/nar/article/48/2/517/5651331

​

Template-jumping prime editing enables large insertion and exon rewriting in vivo.

Chunwei Zheng, Bin Liu, Xiaolong Dong, Nicholas Gaston, Erik J. Sontheimer, Wen Xue*.

Nature Communications. 2023 Jun 8, 14: 3369. https://www.nature.com/articles/s41467-023-39137-6

​

CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment.

Bin Liu, Ali Saber, Hidde J. Haisma.

Drug Discovery Today. 2019 Apr;24(4):955-970. https://pubmed.ncbi.nlm.nih.gov/30849442/

 

A complete list of publications can be found here.

​​